Successful treatment of short stature and delayed puberty in congenital magnesium-losing kidney A J Taylor and T L Dornan
From the Department of Clinical Biochemistry, Hope Hospital, Stott Lane, Salford M6 8HD, UK SUMMARY. Bartter's syndrome is a well described but uncommon disease characterized by hypokalaemia and hyperplasia of the juxtaglomerular apparatus of the kidney. It may present in infancy with failure to thrive and muscle weakness; it commonly causes short stature. I Lesions at different sites within the renal tubule have been proposed as the cause of the syndrome. However, the biochemical abnormalities in many cases can be explained by defective reabsorption of chloride in the ascending loop of Henle, with loss of sodium and water and a secondary increase in renin and aldosterone concentrations.v? Less severe cases have been described which present in adolescence and have tetany as a prominent feature." Primary renal loss of magnesium associated with potassium wasting has been described in such cases and it has been suggested that these can be distinguished from classical Bartter's syndrome by hypocalciuria." This less well characterized disease has been named Welt, Gitelman-Welt or Gitelman syndrome? and may include deficient tubular reabsorption of chloride.! but the sites of magnesium and potassium loss in the kidney are uncertain.! We describe a patient with this syndrome who presented with short stature, delayed puberty and tetany and responded well to magnesium replacement.
Additional key phrases: hypomagnesaemia; hypokalaemia; Barner's syndrome; Gitelman-Weit syndrome CASE REPORT An 18-year-old male had experienced episodes of carpopedal spasm since the age of 11; initially, these occurred every 6 months but were becoming more frequent. No convulsions or loss of consciousness had occurred. He also complained of short stature but felt well between attacks, apart from muscle weakness and a craving for salt. He had never had an erection or nocturnal emission, and did not shave. He was between the third and tenth centiles for height and below the third for weight with poor muscle development and an infantile facial appearance. Tanner stages for pubic hair and genitalia were 3 and 4, respectively, with testicular volumes of 15 mL and 12 mL. Power was symmetrically reduced in all limbs. Trousseau and Chvostek signs were positive. There was no clinical evidence of Correspondence: Dr A J Taylor, Department of Clinical Chemistry, Wythenshawe Hospital, Southmoor Rd, Manchester M23 9LT, UK. 494 hypopituitarism and thyroid function was normal. He was normotensive and did not have polyuria or polydipsia. There was no family history of poor sexual development or carpopedal spasm. His father (who had Crohn's Disease) was on the third centile for height and the younger of his two brothers (age 22) was on the third centile, but muscular. Hypokalaemia and hypomagnesaemia were not present in other family members.
The proband was normocalcaemic (calcium 2'41 mmol/L, albumin 50 giL) but serum K+ (2' 9 mmol/L) and Mg2 + (0' 49 mmol/L) were low, with inappropriately high 24-h urinary excretion of K+ and Mg2 + (42 mmol and 3· 4 mmol respectively), suggesting a primary renal loss. Bone age determined radiologically by the method of Gruhlich and Pyle 9 was 14 years. Serum testosterone was 17 nmol/L (reference was given oral potassium and magnesium supplements. Episodes of tetany were abolished immediately and he reported an increase in muscle power.
Renin activity and aldosterone concentration in samples of plasma collected under controlled conditions before the start of treatment were normal (Table I) . These findings were not typical of classical Bartter's syndrome, in which markedly elevated plasma renin activities and plasma aldosterone concentrations are found in samples taken after overnight recumbency, so an alternative explanation for the clinical and biochemical findings was sought. He was readmitted after discontinuation of therapy for 7 days, and urine and plasma electrolytes were measured daily for 5 days during dietary sodium restriction ( Table 2 ). Plasma renin activities were raised in samples taken after overnight recumbency on two occasions during this admission, but the corresponding aldosterone concentrations were normal or only slightly elevated (Table I) . Glomerular filtration rate determined by clearance of radiolabelled chromium-EDTA was 174 mLI min. Drug and laxative screens were negative. Urinary output of glucose, phosphate, uric acid and amino acids were within normal limits.
His hypokalaemia had not been corrected by up to 50 mmol/day of oral potassium supplementation; it was notable, then, that the hypokalaemia also improved (plasma K + concentration rose from 2' 8 mmol/L to 3· 2 mmol/L) during a period of intravenous infusion of magnesium chloride which raised plasma magnesium from O· 56 mmol/L to 0'72 mmol/L ( Table 2 ). This occurred despite an unchanged dietary intake and without potassium supplementation, suggesting that hypokalaemia was secondary to hypomagnesaemia. The patient was subsequently treated with oral potassium and magnesium chloride infusions at 6-weekly intervals. Only two further episodes of tetany occurred over 2 years, his height is now over the 50th centile, he has attained puberty, his muscle bulk has increased markedly and he is able to lift weights of over 20 kg. Plasma magnesium concentration has remained low, rising transiently to normal after treatment. Plasma K + remains low « 3 mmol/L), unresponsive to increased oral supplements, indomethacin, ibuprofen or amiloride.
Plasma and urine calcium concentrations were determined by an automated cresophthaleincomplexone method, plasma and urine magnesium concentrations by atomic absorptiometry and plasma sodium and potassium concentrations by ion-selective electrodes. Serum testosterone was assayed by radioimmunoassay after extraction, and LH and FSH by immunoradiometric assays. Plasma renin activities were measured by 
DISCUSSION
This patient had a combination of clinical features which have not been described before, namely hypomagnesaemia and hypokalaemia due to a primary renal loss of magnesium and delayed puberty with short stature which responded to magnesium supplementation. The most striking biochemical feature was profound hypomagnesaemia. Depletion of magnesium has many possible causes (Table 3) . 10, 11 The excretion in urine of an amount of magnesium inappropriate to the plasma concentration is strong evidence Table 3 could be eliminated in this patient on clinical or biochemical grounds; glomerular filtration rate was normal, there was no acidosis, phosphaturia, aminoaciduria, uricosuria or glycosuria, and a urine drug screen was negative. Diuretic abuse, particularly of thiazides, can cause hypomagmesaemia, and might be missed on a routine drug screen. However, there was no circumstantial evidence to suggest the patient was taking diuretics, or had access to them, so more intensive searches for the drugs were not undertaken. The other marked biochemical abnormality, hypokalaemia, might have been due to an independent renal loss of the ion but was more likely secondary to hypornagnesaemia.P Our patient had many clinical features suggestive of Bartter's syndrome including salt craving, muscle weakness, short stature and cramps. Other features of Bartter's syndrome (polyuria, anorexia, constipation and convulsions) were absent. This syndrome may present at any age, but is usually detected first in childhood. Classical biochemical features include elevated plasma concentrations of renin and aldosterone, without hypertension or oedema. Hypomagnesaernia and hypokalaemia due to renal loss may also be found. Hyperplasia of the juxtaglomerular apparatus is usually found on renal biopsy, but we did not obtain a renal biopsy from our patient. The finding of normal or only slightly raised aldosterone concentrations in plasma is atypical for Bartter's syndrome: it is possible that hypokalaemia may have suppressed the secretion of aldosterone, although hypokalaemia was not profound and, before treatment, the plasma renin activity was not markedly elevated either.
Whilst our patient might be regarded as an atypical case of Bartter's syndrome, there is increasing evidence that this syndrome is itself heterogenous. 14 A 'late-onset' form of the syndrome has been described, with renal wasting of magnesium as a key feature.! This variant has been termed Gitelman or Gitelman-Welt syndrome, and is probably pathophysiologically distinct from classical Bartter's syndrome; our patient fits well with descriptions of that disorder, except that plasma renin activity was relatively low before treatment, though more typically high on repeat sampling after treatment had commenced. Hypocalciuria was found in our patient, as in other reported cases of Gitelman syndrome, distinct from the normal or elevated urinary excretion of calcium in classical Bartter's syndrome.' Hypocalciuria is sometimes reported as a characteristic feature of Bartter's syndrome. This may be because some authors fail to differentiate the different clinical presentations of the disorder. It has been proposed that a malor calcium:creatinine ratio in urine of < O·2 discriminates between the two syndromes; this ratio was < 0·05 on three occasions in our patient. Defects in the renal tubular handling of water are seen in some patients with classical Bartter's syndrome," but not in Gitelman syndrome." We did not assess this formally in our patient because he had no symptoms of polyuria or polydipsia.
Our patient illustrates how florid the effects of magnesium depletion may be. Tetany may be due
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to associated hypocalcaemia, not seen in our patient, or to hypomagnesaemia per se. 15 Short stature, which is reported in both Bartter's and Gitelman syndrome.s-" and pubertal delay, which has not previously been described in Gitelman syndrome, might be due to the tissue effects of chronic hypomagnesaemia and hypokalaemia. However, potassium supplements are said to fail to improve growth in Bartter's syndrome;' and improved stature following magnesium therapy was not noted in two reviews of these syndromes.V Magnesium is required in almost every step of protein synthesis, energy and nucleotide metabolism and cell replication. Magnesium depletion in rats may lead to growth impairment through suppression of release of serum insulin-like growth factor-l (IGF-l).17 Measurements of (IGF-I) were unavailable on this patient, but the response of this factor to magnesium therapy would have been of potential interest. However, data on serum growth hormone and IGF-I in Bartter's syndrome is extremely sparse: only one patient has been studied. IS Whether direct or hormonally-mediated, the effect of successful replacement of magnesium on growth and pubertal delay in our patient was notable.
Most publications on Bartter's and Gitelman syndromes are directed at classification and pathophysiology rather than treatment. Hypokalaemia in Bartter's syndrome may respond to non-steroidal anti-inflammatory agents, amiloride, spironolactone, and, in some cases, captcpril.'? It has been noted that growth retardation responded poorly to potassium supplements] and magnesium replacement. 5, 6 The treatment of Gitelman syndrome has received little attention. Magnesium and potassium chloride therapy has been used" and the condition has been described as 'benign'. 5 Our patient was unresponsive to ibuprofen, indomethacin and amiloride; captopril has not been used because aldosterone concentrations are normal. On potassium supplements alone, his symptoms improved, but he still had mild episodes of tetany. Oral magnesium caused unacceptable diarrhoea, so we have given him 6 weekly magnesium infusions, on which he remains asymptomatic until his infusion is due, and he has grown to a normal adult height. We are currently testing different oral magnesium preparations for efficiency and acceptability.
We present this case to emphasize the value of measuring plasma magnesium in patients with tetany or growth failure of uncertain origin,20 to add further weight to the proposed distinction between Bartter's and Gitelman syndromes, which have important differences in prognosis and management,5,6,8 and to confirm the value of urinary calcium excretion as a discriminant between them. The difficulty in achieving adequate oral replacement of magnesium in our patient is an unresolved clinical problem.
